Pioglitazone Suppresses CXCR7 Expression To Inhibit Human Macrophage Chemotaxis through Peroxisome Proliferator-Activated Receptor gamma

作者：Zhao Duo; Zhu Zhicheng; Li Dan; Xu Rihao; Wang Tiance; Liu Kexiang^*

来源：Biochemistry, 2015, 54(45): 6806-6814.

DOI：10.1021/acs.biochem.5b00847

Cardiovascular disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Pioglitazone, the widely used thiazolidinedione, is shown to be efficient in the prevention of cardiovascular complications of T2DM. In this study, we report that pioglitazone inhibits CXCR7 expression and thus blocks chemotaxis in differentiated macrophage without perturbing cell viability or macrophage differentiation. In addition, pioglitazone-mediated CXCR7 suppression and chemotaxis inhibition occur via activating peroxisome proliferator-activated receptor gamma (PPAR gamma) but not PPAR alpha in differentiated macrophage. More importantly, pioglitazone therapy-induced PPAR gamma activation suppresses CXCR7 expression in human carotid atherosclerotic lesions. Collectively, our data demonstrate that pioglitazone suppresses CXCR7 expression to inhibit human macrophage chemotaxis through PPAR gamma.

• 出版日期2015-11-17
• 单位吉林大学